Objective: Colorectal cancers (CRC) are the 3rd most common malignancies worldwide. The evaluation of prognostic factors is critical for both disease progression and treatment planning. With the increasing research on the role of inflammation in tumor development and metastasis, inflammation markers have gained importance. This study aims to investigate the effects of the Systemic Immune-Inflammation Index (SII) on CRC survival and provide new recommendations for clinical practice. Material and Methods: The data of patients who underwent surgery for CRC between August 2017 and 2024 were retrospectively analyzed. Patients' demographic data, laboratory findings, and operative findings were collected. SII values were calculated using preoperative laboratory test results with the neutrophil*platelet/ lymphocyte formula. Patients who underwent surgery for benign reasons, those who had emergency surgeries, and those with missing data were excluded from the study. Results: A total of 96 patients, including 43 (44.79%) females and 53 (55.21%) males aged between 36 and 85, were included in the study. A statistically significant relationship was found between SII values and regional lymph nodes, N stage, and tumor size, lymph node metastasis, distant metastasis (TNM) stage. The effect of neutrophil count and SII values on CRC survival was analyzed, but no statistically significant findings were observed (p>0.05). Conclusion: In clinical practice, SII values may assist in determining treatment strategies. Although SII was not independently associated with overall survival, it was significantly correlated with tumor burden related parameters (N stage, TNM stage), suggesting an indirect prognostic role. Future studies are needed to better understand the prognostic value of SII and to develop personalized treatment approaches.
Özcan et al. (Thu,) studied this question.